An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
Autor: | Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Anh L. Ngo, Alan D. Kaye, Rachel J. Kaye, Elyse M. Cornett, Omar Viswanath |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: | |
Zdroj: | Pain and Therapy, Vol 9, Iss 1, Pp 195-215 (2020) |
Druh dokumentu: | article |
ISSN: | 2193-8237 2193-651X |
DOI: | 10.1007/s40122-020-00159-3 |
Popis: | Abstract Migraine headache is a common, chronic, debilitating disease with a complex etiology. Current therapy for migraine headache comprises either treatments targeting acute migraine pain or prophylactic therapy aimed at increasing the length of time between migraine episodes. Recent evidence suggests that calcium gene-related peptide (CGRP) is a critical component in the pathogenesis of migraines. Fremanezumab, a monoclonal antibody against CGRP, was recently approved by the Food and Drug Administration (FDA) after multiple studies showed that it was well-tolerated, safe, and effective in the treatment of migraines. Further research is needed to elucidate the long-term effects of fremanezumab and CGRP-antagonists in general, and additional data is required in less healthy patients to estimate its effects in these populations and potentially increase the eligible group of recipients. This is a comprehensive review of the current literature on the efficacy and safety of fremanezumab for the treatment of chronic migraine. In this review we provide an update on the epidemiology, pathogenesis, diagnosis, and current treatment of migraine, and summarize the evidence for fremanezumab as a treatment for migraine. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |